<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10593">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645164</url>
  </required_header>
  <id_info>
    <org_study_id>011 101 09 002</org_study_id>
    <nct_id>NCT00645164</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment</brief_title>
  <official_title>Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthpoint</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healthpoint</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The product is being tested to see if exposure to light causes photoallergic reactions on
      the skin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Frequency Distribution of Skin Irritation Scores</measure>
    <time_frame>48-hours post irradiation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Scores based on skin irritation scale of 0 (no reaction) to 7 (large vesiculo-bullous reaction) in whole units. Photoallergic reactions were characterized by irritation scores of 3 or higher.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Xenaderm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject serves as own control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ointment Vehicle</intervention_name>
    <description>Subject acts as own control. 20 mg under Finn chambers</description>
    <arm_group_label>Xenaderm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenaderm</intervention_name>
    <description>20 mg under Finn chambers</description>
    <arm_group_label>Xenaderm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

        Exclusion Criteria:

          -  Less than 18 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Stanfield, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Suncare Research Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Suncare Research Laboratories</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <lastchanged_date>June 1, 2010</lastchanged_date>
  <firstreceived_date>March 24, 2008</firstreceived_date>
  <firstreceived_results_date>October 8, 2008</firstreceived_results_date>
  <responsible_party>
    <name_title>H. B. Slade, MD</name_title>
    <organization>Healthpoint</organization>
  </responsible_party>
  <keyword>wound healing</keyword>
  <keyword>photoallergenicity</keyword>
  <keyword>Healthy subjects</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Planned: Approximately 60 evaluable subjects. Analyzed: 59 subjects were enrolled in the study, of which 58 were randomized and received test article. 7 subjects were prematurely withdrawn â€“ 1 prior to receiving test articles; 52 subjects completed the study and were evaluable.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Xenaderm</title>
          <description>Subject serves as own control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xenaderm</title>
          <description>Subject serves as own control</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="59"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="59"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38.8" spread="12.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="59"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency Distribution of Skin Irritation Scores</title>
        <description>Scores based on skin irritation scale of 0 (no reaction) to 7 (large vesiculo-bullous reaction) in whole units. Photoallergic reactions were characterized by irritation scores of 3 or higher.</description>
        <time_frame>48-hours post irradiation</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Analysis was based on number of subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenaderm</title>
            <description>Subject serves as own control</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Frequency Distribution of Skin Irritation Scores</title>
            <description>Scores based on skin irritation scale of 0 (no reaction) to 7 (large vesiculo-bullous reaction) in whole units. Photoallergic reactions were characterized by irritation scores of 3 or higher.</description>
            <units>Scores on a scale</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>No reaction (0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Minimal (doubtful) response (1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Definite, mild erythema (2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate erythema (3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema with slight edema (4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema with marked edema (5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema w/infiltration w/wo vesiculation (6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Large vesiculo-bullous reaction (7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Xenaderm</title>
          <description>Subject serves as own control</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Burning at test site</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Itching at test site</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tape reaction</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Interpretation of frequency distribution of skin irritation scores was based on long term experience with this type of testing.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Herbert B. Slade MD, FAAAAI</name_or_title>
      <organization>DFB Pharmaceuticals</organization>
      <phone>817.302.3919</phone>
      <email>bert.slade@dfbpharmaceuticals.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
